You can download the article here
Conference call with patient organizations (27 OCTOBER ’16)
At the latest end-of-the-month AIDNPC telephone conference hosted by the sponsor, Orphazyme ApS, the following update on the recruitment into the ‘-001’ and ‘-002’ Studies was presented. Over the last month, no more patients have enrolled in neither of the ‘-001’ and ‘-002’ Studies, leaving the total at 35 patients enrolled to date at 12 European sites. Of these, in the ‘-002’ Study, still a total of 3 patients have been enrolled to date at the following site:
Recruitment into the 002 Interventional Study
While Orphazyme reports making headway through many of the regulatory steps at each country, the main obstacles are currently getting contracts approved at individual sites and/or getting reviewed by local ethics committees. Varying calendars and deadline schedules for these also play into the timelines.
Orphazyme believes it is closest getting enrolment started at the sites in Germany, UK, and Spain.
The three patients in Denmark have recently completed their 3-month visit.
US sites have been announced
Of particular interest to the US NP-C community, Orphazyme announced that the three US sites that are being established can now be announced. The three US sites and their contact details are as follows:
Clinical design overview
The graphic below illustrates the design of the ‘-002’ Study, including number and timing of patients visits to the sites. An escape route is provided for patients that experience an unacceptable rate of progression of the disease.
We encourage the sharing of above information with the patient community.
The next AIDNPC call is schedule for Thursday November 24th at 15h EDT.
Visit the AIDNPC Clinical Programme website: www.AIDNPC.com